Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Are The Growth Projections For The Next Generation Immunotherapies Market Size During 2025–2029?
The next generation immunotherapies market size has demonstrated rapid expansion in recent years. It is projected to increase from $133.81 billion in 2024 to $150.12 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 12.2%. The historical growth experienced by this market can be attributed to the rising prevalence of oncology, an increase in research and development investments, a surge in government initiatives, heightened government expenditure on health, and the expansion of approved indications.
The next generation immunotherapies market is anticipated to experience substantial growth in the coming years. It is projected to reach $235.85 billion by 2029, expanding at a compound annual growth rate (CAGR) of 12.0%. This expansion during the forecast period is primarily driven by the increasing incidence of cancer, escalating healthcare expenditure, wider adoption of chimeric antigen receptor (CAR) T-cell therapy, the growing impact of chronic diseases, and enhanced research into next-generation drugs. Key trends throughout the forecast period include a transition towards combination therapies, ongoing technological progress, innovative therapeutic strategies, developments in personalized medicine, and improvements in regulatory support.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21231&type=smp
What Are The Emerging Market Drivers Creating New Opportunities In The Next Generation Immunotherapies Industry?
The rising prevalence of cancer is projected to propel the expansion of the next-generation immunotherapies market. Cancer, a group of diseases marked by the uncontrolled growth and spread of abnormal cells in the body, sees its prevalence influenced by factors such as aging populations, lifestyle shifts, environmental exposures, and better detection methods. Next-generation immunotherapies provide advanced, targeted treatments that enhance the body’s immune response to cancer, offering improved effectiveness, durability, and personalization. For instance, in May 2024, reports from the National Cancer Institute (NCI), a US-based government agency, revealed nearly 20 million new cancer cases and 9.7 million cancer-related deaths globally in 2022, with projections for 2040 estimating 29.9 million new cases and 15.3 million cancer-related deaths. This increasing prevalence of cancer is thus driving the growth of the next-generation immunotherapies market.
Which Key Segments Fueling The Next Generation Immunotherapies Market?
The next generation immunotherapiesmarket covered in this report is segmented –
1) By Drug Class: Monoclonal Antibodies; Antibody-Drug Conjugates – ADC’s; Angiotensin-Converting Enzyme (ACE) Inhibitors; Immune Checkpoint Inhibitors
2) By Route Of Administration: Intravenous; Parenteral; Intratumoral; Subcutaneous; Oral
3) By Distribution Channel: Hospital Pharmacies; Clinical Pharmacies; Other Distribution channels
Subsegments:
1) By Monoclonal Antibodies: Anti-PD-1 Antibodies; Anti-PD-L1 Antibodies; Anti-CTLA-4 Antibodies; Anti-CD20 Antibodies; Other Monoclonal Antibodies
2) By Antibody-Drug Conjugates (ADC’s): HER2-targeted ADCs; CD30-targeted ADCs; CD19-targeted ADCs; Other ADCs
3) By Angiotensin-Converting Enzyme (ACE) Inhibitors: ACE Inhibitors For Cancer Therapy; ACE Inhibitors For Other Indications
4) By Immune Checkpoint Inhibitors: PD-1 Or PD-L1 Inhibitors; CTLA-4 Inhibitors; Other Immune Checkpoint Inhibitors
What Trends Are Redefining The Next Generation Immunotherapies Market Dynamics?
Major companies operating in the next-generation immunotherapies market are prioritizing the development of innovative therapies, such as CAR T-cell therapy, to address cancers, autoimmune diseases, and infectious diseases. CAR T-cell therapy is a form of immunotherapy where a patient’s T cells, a type of immune cell, are genetically modified to express chimeric antigen receptors (CARs). For instance, in January 2025, Immuneel Therapeutics Private Limited, an India-based cell and gene therapy startup, introduced Qartemi, India’s first CAR T-cell therapy. This therapy, aimed at adult B-cell non-Hodgkin lymphoma, functions by genetically altering a patient’s immune cells to target and eliminate cancer cells, thus presenting a highly effective and personalized treatment option. It extends renewed hope to patients for whom conventional treatments have proven unsuccessful, with the added advantage of being more affordable than comparable global options.
Which Key Players Are Driving Competition In The Next Generation Immunotherapies Market?
Major companies operating in the next generation immunotherapies market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc., Incyte Corporation, BioNTech SE, Xencor Inc., Fate Therapeutics Inc., Immatics N.V., Atara Biotherapeutics Inc., Menarini Group, Alpine Immune Sciences Inc., Mereo Biopharma Group plc, Immunomic Therapeutics Inc., Indaptus Therapeutics Inc.
Download The Full Report For Exclusive Market Findings:
What Regional Growth Trends Are Shaping The Next Generation Immunotherapies Market Outlook?
North America was the largest region in the next-generation immunotherapies market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next generation immunotherapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Next Generation Immunotherapies Market Report:
https://www.thebusinessresearchcompany.com/customise?id=21231&type=smp
Browse Through More Reports Similar to the Global Next Generation Immunotherapies Market 2025, By The Business Research Company
Clinical Oncology Next Generation Sequencing Global Market Report 2025
Next Generation Sequencing Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/next-generation-sequencing-global-market-report
Next Generation Military Power Supply Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model